Results 21 to 30 of about 54,491 (199)
Research and Practice in Thrombosis and Haemostasis, 2020 Background Heparins and heparinoids interfere with functional clotting assays used for lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not provide clear guidance on this matter.
Pieter M.M. De Kesel +1 more
doaj +1 more source
Identification of serum biomarkers in dogs naturally infected with Babesia canis canis using a proteomic approach [PDF]
, 2014 <b>Background</b><p></p> Canine babesiosis is a tick-borne disease that is caused by the haemoprotozoan parasites of the genus Babesia.
Burchmore, Richard +5 more
core +3 more sources
Loss of maternal annexin A5 increases the likelihood of placental platelet thrombosis and foetal loss [PDF]
, 2012 Antiphospholipid syndrome is associated with an increased risk of thrombosis and pregnancy loss. Annexin A5 (Anxa5) is a candidate autoantigen. It is not known, however, whether endogenous Anxa5 prevents foetal loss during normal pregnancy.
Brachvogel, Bent +11 more
core +1 more source
Lupus anticoagulant hypoprothrombinemia syndrome associated with a hemorrhagic ovarian cyst in a girl with systemic lupus erythematosus : a case report [PDF]
Childhood Kidney DiseasesLupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare entity characterized by the presence of lupus anticoagulant (LA) and prothrombin (factor II) deficiency. It may cause severe bleeding contrary to classical antiphospholipid syndrome. Here,
Min Hwa Son, Hyung Eun Yim
doaj +1 more source
Sickle cell trait: a cause of abdominal pain and pulmonary embolism
Revista de la Facultad de Ciencias Médicas de Córdoba, 2020 Introduction: Sickle cell trait (SCT) is a rare and underdiagnosed disorder in the Argentinian population. In this condition, individuals carry the mutation of the HbS gene in one of the two beta-globin genes.
Emanuel José Saad +4 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with ...
Steven Andrew Baker +4 more
doaj +1 more source
The role of hypercoagulability in the development of osteonecrosis of the femoral head
Orthopedic Reviews, 2012 Despite the large number of the outstanding researches, pathogenesis of osteonecrosis remains unknown. During the last decades the hypothesis that increased intravascular coagulation may be the pathogenetic mechanism which leads to osteonecrosis is ...
Marios G. Lykissas +4 more
doaj +1 more source
Frontiers in Neurology, 2020 Background: Lupus anticoagulant (LA) owns procoagulant properties in vivo and prolongs phospholipid-dependent clotting times in vitro. The prolonged in vitro clotting time can be misinterpreted as a bleeding disorder.
Aydin Huseynov +10 more
doaj +1 more source
Frontiers in Immunology, 2022 In CD38-deficient (Cd38-/-) mice intraperitoneal injection of pristane induces a lupus-like disease, which is milder than that induced in WT mice, showing significant differences in the inflammatory and autoimmune processes triggered by pristane ...
Paula Carrillo-Rodríguez +19 more
doaj +1 more source
Lupus anticoagulant: a clinical and laboratory diagnostic dilemma
Journal of Pathology of Nepal, 2022 Lupus anticoagulants are a group of diverse autoantibodies that interfere in vitro in phospholipid-dependent clotting tests, and inhibit both the common and intrinsic pathways of coagulation. Paradoxically, they are implicated to cause hypercoagulability,
Shalini Trivedi +4 more
semanticscholar +1 more source